French medical technology company Affluent Medical has announced positive results from its SCOPE 1 clinical trial validating the efficacy of Kardiozis technology: an endoprosthesis using thrombogenic fibre embolisation of the aneurysm sac to prevent endoleak and reintervention.

Affluent Medical

Image: Affluent Medical releases positive results for KARDIOZIS technology. Photo: Courtesy of Affluent Medical.

Affluent Medical stated that the SCOPE 1 clinical trial began in 2013 at Marie Lannelongue hospital – Le Plessis-Robinson, in collaboration with Paris-Sud Saclay University and Paris-Est University, France.

The randomized, prospective, multi-centric clinical trial assessed efficacy and clinical outcomes of embolization of the aneurysm sac using thrombogenic fibers when performing a conventional EndoVascular Aneurysm Repair (EVAR).

The trial involved 102 patients in two arms and data records from 91 patients were analyzed. The control group had 45 patients, who were implanted with EVAR only and 46 patients in the study group had been implanted with EVAR and parallel thrombogenic fibers embolization of the aneurysm sac.

A 24-month follow-up after implant, showed that the study group of patients had shown significant improvement of freedom from endoleaks and secondary interventions and aneurysm volume and diameter had also reduced.

It is claimed that no complications related to thrombogenic fibers embolization were observed.

Rate of secondary operations and endoleaks had significantly reduced in the study group from 78% to 47%. Significant reduction of aneurysm volume of about 55% was observed in patients in the study group compared to patients in the control Group at 24 months.

Affluent Medical CEO Daniele Zanotti said: “KARDIOZIS proprietary technology has been conceived to achieve the same results but avoiding the complexity of an additional procedure, by effectively preventing type II endoleaks which is the main complication after an EVAR implant. This trial confirms, with strong evidence, the therapeutic value of the KARDIOZIS technology, which has the potential of achieving far superior clinical outcomes, reduced need for reintervention and fewer control visits.

“KARDIOZIS technology, proven in the SCOPE 1 trial, can be applied both to existing endoprosthesis on the market, via corporate partnerships, and to Affluent own endoprosthesis under development. We thank Prof. Fabre and the whole team of investigators which has conducted the SCOPE 1 trial to this spectacular result.”

KARDIOZIS is a new implant which is expected to be launched in Europe by 2021. It is touted to be the first endovascular prosthesis that can prevent endoleaks in life threatening abdominal aortic aneurysm, which affects 5 to 10% of men from age 65 to 80.

It is a minimally invasive prosthesis which differs from other endovascular prostheses that are currently available in the market, as it has designed with thrombogenic fibers on the outer wall of the prosthesis.

The length and distribution of these fibers allows them to embolize the aneurysm after implantation, as potently as the thrombogenic fibers that were inserted in the aneurysm sac in the SCOPE-1 trial after the implantation of a conventional endovascular prosthesis.

The device can help in reducing endoleaks and the size of aneurysm and then can prevent such complications. Affluent Medical claims that KARDIOZIS could become a leading treatment for abdominal aortic aneurysm.